tbuckley/cabot-search huggingface dataset:
Tooth‐ and implant‐related prognostic factors in treatment planning
Authors: Anastasiya Orishko, Jean‐Claude Imber, Andrea Roccuzzo, Alexandra Stähli, Giovanni E. Salvi
Journal: Periodontology 2000 (2024)

Abstract Following a comprehensive patient examination, including the assessment of periodontal and peri‐implant diseases as well as considering the patient's needs, a pretherapeutic prognosis for each tooth and implant is given. Teeth and implants with a secure pretherapeutic prognosis require simple procedures and may be regarded as secure abutments for function and with a doubtful pretherapeutic prognosis usually need a comprehensive therapy. Such teeth and implants must be brought into the category with a secure prognosis by means of additional therapy such as endodontic, restorative, and surgical procedures. Teeth and implants with a hopeless pretherapeutic prognosis should be extracted/explanted during the initial phase of cause‐related therapy (i.e., infection control). For example, teeth with vertical root fracture or unrestorable caries and implants with mobility or unrestorable malposition fall into the category of hopeless units. The primary goal of periodontal and peri‐implant therapy should be to arrest disease progression. The latest consensus statement highlights that periodontitis can be successfully controlled and treated teeth can be retained for life. Nevertheless, for patients with uncontrolled contributing factors, the endpoints might not always be achievable, and low disease activity may be an acceptable therapeutic goal. Similarly, the management of peri‐implantitis frequently requires surgical intervention following nonsurgical therapy due to incomplete treatment outcomes. Different surgical modalities can be effective and lead to significant improvement; however, achieving complete resolution of peri‐implantitis is challenging, not always predictable, and can depend on multiple baseline factors. Therefore, this review aims at summarising available evidence on the rationale for incorporating systemic, lifestyle‐related, clinical, and radiographic prognostic factors into treatment planning of patients diagnosed with periodontal and peri‐implant diseases.
Estrogen deficiency‐mediated osteoimmunity in postmenopausal osteoporosis
Authors: Yao Yao, Xiaoyu Cai, Yue Chen, Meng Zhang, Caihong Zheng
Journal: Medicinal Research Reviews (2024)

Abstract Postmenopausal osteoporosis (PMO) is a common disease associated with aging, and estrogen deficiency is considered to be the main cause of PMO. Recently, however, osteoimmunology has been revealed to be closely related to PMO. On the one hand, estrogen deficiency directly affects the activity of bone cells (osteoblasts, osteoclasts, osteocytes). On the other hand, estrogen deficiency‐mediated osteoimmunity also plays a crucial role in bone loss in PMO. In this review, we systematically describe the progress of the mechanisms of bone loss in PMO, estrogen deficiency‐mediated osteoimmunity, the differences between PMO patients and postmenopausal populations without osteoporosis, and estrogen deficiency‐mediated immune cells (T cells, B cells, macrophages, neutrophils, dendritic cells, and mast cells) activity. The comprehensive summary of this paper provides a clear knowledge context for future research on the mechanism of PMO bone loss.
Regional desynchronization of microglial activity is associated with cognitive decline in Alzheimer’s disease
Authors: Artem Zatcepin, Johannes Gnörich, Boris-Stephan Rauchmann, Laura M Bartos, Stephan Wagner, Nicolai Franzmeier, Maura Malpetti, Xianyuan Xiang, Yuan Shi, Samira Parhizkar, Maximilian Grosch, Karin Wind-Mark, Sebastian T Kunte, Leonie Beyer, Carolin Meyer, Desirée Brösamle, Ann-Christin Wendeln, Collins Osei-Sarpong, Steffanie Heindl, Arthur Liesz, Sophia Stoecklein, Gloria Biechele, Anika Finze, Florian Eckenweber, Simon Lindner, Axel Rominger, Peter Bartenstein, Michael Willem, Sabina Tahirovic, Jochen Herms, Katharina Buerger, Mikael Simons, Christian Haass, Rainer Rupprecht, Markus J Riemenschneider, Nathalie L Albert, Marc Beyer, Jonas J Neher, Lars Paeger, Johannes Levin, Günter U Höglinger, Robert Perneczky, Sibylle I Ziegler, Matthias Brendel
Journal: Molecular Neurodegeneration (2024)
Long-term mortality and health-related quality of life with lower versus higher oxygenation targets in intensive care unit patients with COVID-19 and severe hypoxaemia
Authors: Elena Crescioli, Frederik Mølgaard Nielsen, Anne-Marie Bunzel, Anne Sofie Broberg Eriksen, Martin Siegemund, Lone Musaeus Poulsen, Anne Sofie Andreasen, Morten Heiberg Bestle, Susanne Andi Iversen, Anne Craveiro Brøchner, Thorbjørn Grøfte, Thomas Hildebrandt, Jon Henrik Laake, Maj-Brit Nørregaard Kjær, Theis Lange, Anders Perner, Thomas Lass Klitgaard, Olav Lilleholt Schjørring, Bodil Steen Rasmussen
Journal: Intensive Care Medicine (2024)
Virally delivered CMYA5 enhances the assembly of cardiac dyads
Authors: Fujian Lu, Carter Liou, Qing Ma, Zexuan Wu, Bingqing Xue, Yu Xia, Shutao Xia, Michael A Trembley, Anna Ponek, Wenjun Xie, Kevin Shani, Raul H Bortolin, Maksymilian Prondzynski, Paul Berkson, Xiaoran Zhang, Francisco J Naya, Kenneth C Bedi, Kenneth B Margulies, Donghui Zhang, Kevin K Parker, William T Pu
Journal: Nature Biomedical Engineering (2024)
Sex-biased neural encoding of threat discrimination in nucleus accumbens afferents drives suppression of reward behavior
Authors: Jessie Muir, Eshaan S Iyer, Yiu-Chung Tse, Julian Sorensen, Serena Wu, Rand S Eid, Vedrana Cvetkovska, Karen Wassef, Sarah Gostlin, Peter Vitaro, Nick J Spencer, Rosemary C Bagot
Journal: Nature Neuroscience (2024)
Multiligament knee injury (MLKI): an expert consensus statement on nomenclature, diagnosis, treatment and rehabilitation
Authors: Iain Robert Murray, Navnit S Makaram, Andrew G Geeslin, Jorge Chahla, Gilbert Moatshe, Kay Crossley, Michelle E Kew, Aileen Davis, Maria Tuca, Hollis Potter, Dina C Janse van Rensburg, Carolyn A Emery, SeungPyo Eun, Hege Grindem, Frank R Noyes, Robert G Marx, Chris Harner, Bruce A Levy, Enda King, James L Cook, Daniel B Whelan, George F Hatch, Christopher J Wahl, Kristian Thorborg, James J Irrgang, Nicolas Pujol, Michael J Medvecky, Michael J Stuart, Aaron J Krych, Lars Engebretsen, James P Stannard, Peter MacDonald, Romain Seil, Gregory C Fanelli, Travis G Maak, K Donald Shelbourne, Evert Verhagen, Volker Musahl, Michael T Hirschmann, Mark D Miller, Robert C Schenck, Robert F LaPrade
Journal: British Journal of Sports Medicine (2024)

Multiligament knee injuries (MLKIs) represent a broad spectrum of pathology with potentially devastating consequences. Currently, disagreement in the terminology, diagnosis and treatment of these injuries limits clinical care and research. This study aimed to develop consensus on the nomenclature, diagnosis, treatment and rehabilitation strategies for patients with MLKI, while identifying important research priorities for further study. An international consensus process was conducted using validated Delphi methodology in line with British Journal of Sports Medicine guidelines. A multidisciplinary panel of 39 members from 14 countries, completed 3 rounds of online surveys exploring aspects of nomenclature, diagnosis, treatment, rehabilitation and future research priorities. Levels of agreement (LoA) with each statement were rated anonymously on a 5-point Likert scale, with experts encouraged to suggest modifications or additional statements. LoA for consensus in the final round were defined ‘a priori’ if &gt;75% of respondents agreed and fewer than 10% disagreed, and dissenting viewpoints were recorded and discussed. After three Delphi rounds, 50 items (92.6%) reached consensus. Key statements that reached consensus within nomenclature included a clear definition for MLKI (LoA 97.4%) and the need for an updated MLKI classification system that classifies injury mechanism, extent of non-ligamentous structures injured and the presence or absence of dislocation. Within diagnosis, consensus was reached that there should be a low threshold for assessment with CT angiography for MLKI within a high-energy context and for certain injury patterns including bicruciate and PLC injuries (LoA 89.7%). The value of stress radiography or intraoperative fluoroscopy also reached consensus (LoA 89.7%). Within treatment, it was generally agreed that existing literature generally favours operative management of MLKI, particularly for young patients (LoA 100%), and that single-stage surgery should be performed whenever possible (LoA 92.3%). This consensus statement will facilitate clinical communication in MLKI, the care of these patients and future research within MLKI.
Cryotherapy for treating soft tissue injuries in sport medicine: a critical review
Authors: Sebastien Racinais, Valentin Dablainville, Yohan Rousse, Mohammed Ihsan, Marie-Elaine Grant, Wolfgang Schobersberger, Richard Budgett, Lars Engebretsen
Journal: British Journal of Sports Medicine (2024)

Sports medicine physicians and physiotherapists commonly use cryotherapy (eg, ice application) postinjury to decrease tissue temperature with the objective of reducing pain, limiting secondary injury and inflammation, and supporting healing. However, besides the analgesic effect of cryotherapy, a literature search revealed no evidence from human studies that cryotherapy limits secondary injury or has positive effects on tissue regeneration. Thus, our current understanding of the potential mechanisms and applications of cryotherapy largely relies on the results from animal studies. Importantly, treatment should not aim at obliterating the inflammatory and regeneration processes but instead aim to restore an adapted/normal regulation of these processes to improve function and recovery. However, some animal studies suggest that cryotherapy may delay or impair tissue regeneration. With the translation of laboratory animal studies to human sport medicine being limited by different injury and muscle characteristics, the effect of cryotherapy in patients with musculoskeletal injuries is uncertain. Thus, pending the results of human studies, cryotherapy may be recommended in the first 6 hours following an injury to reduce pain (and possibly haematoma), but it should be used with caution beyond 12 hours postinjury as animal studies suggest it may interfere with tissue healing and regeneration.
EPAS1 Attenuates Atherosclerosis Initiation at Disturbed Flow Sites Through Endothelial Fatty Acid Uptake
Authors: Daniela Pirri, Siyu Tian, Blanca Tardajos-Ayllon, Sophie Irving, Francesco Donati, Scott P. Allen, Tadanori Mammoto, Gemma Vilahur, Lida Kabir, Jane Bennett, Yasmin Rasool, Charis Pericleous, Guianfranco Mazzei, Liam McAllan, William R. Scott, Thomas Koestler, Urs Zingg, Graeme Birdsey, Clint Miller, Torsten Schenkel, Emily V. Chambers, Mark Dunning, Jovana Serbanovic-Canic, Francesco Botrè, Akiko Mammoto, Suowen Xu, Elena Osto, Weiping Han, Maria Fragiadaki, Paul C. Evans
Journal: Circulation Research (2024)

Atherosclerotic plaques form unevenly due to disturbed blood flow, causing localized endothelial cell (EC) dysfunction. Obesity exacerbates this process, but the underlying molecular mechanisms are unclear. The transcription factor EPAS1 (HIF2A) has regulatory roles in endothelium, but its involvement in atherosclerosis remains unexplored. This study investigates the potential interplay between EPAS1, obesity, and atherosclerosis.
Macrophage-Expressed Coagulation Factor 7 Promotes Adverse Cardiac Remodeling
Authors: Venkata Garlapati, Qi Luo, Jens Posma, Melania Aluia, Than Son Nguyen, Kristin Grunz, Michael Molitor, Stefanie Finger, Gregory Harms, Tobias Bopp, Wolfram Ruf, Philip Wenzel
Journal: Circulation Research (2024)

Excess fibrotic remodeling causes cardiac dysfunction in ischemic heart disease, driven by MAP (mitogen-activated protein) kinase-dependent TGF-ß1 (transforming growth factor-ß1) activation by coagulation signaling of myeloid cells. How coagulation-inflammatory circuits can be specifically targeted to achieve beneficial macrophage reprogramming after myocardial infarction (MI) is not completely understood.
Experimental TET2 Clonal Hematopoiesis Predisposes to Renal Hypertension Through an Inflammasome-Mediated Mechanism
Authors: Ariel H. Polizio, Lucila Marino, Kyung-Duk Min, Yoshimitsu Yura, Luca Rolauer, Jesse D. Cochran, Megan A. Evans, Eunbee Park, Heather Doviak, Emiri Miura-Yura, Miranda E. Good, Abigail G. Wolpe, Maria Grandoch, Brant E. Isakson, Kenneth Walsh
Journal: Circulation Research (2024)

BACKGROUND: Hypertension incidence increases with age and represents one of the most prevalent risk factors for cardiovascular disease. Clonal events in the hematopoietic system resulting from somatic mutations in driver genes are prevalent in elderly individuals who lack overt hematologic disorders. This condition is referred to as age-related clonal hematopoiesis (CH), and it is a newly recognized risk factor for cardiovascular disease. It is not known whether CH and hypertension in the elderly are causally related and, if so, what are the mechanistic features. METHODS: A murine model of adoptive bone marrow transplantation was employed to examine the interplay between Tet2 (ten-eleven translocation methylcytosine dioxygenase 2) clonal hematopoiesis and hypertension. RESULTS: In this model, a subpressor dose of Ang II (angiotensin II) resulted in elevated systolic and diastolic blood pressure as early as 1 day after challenge. These conditions led to the expansion of Tet2-deficient proinflammatory monocytes and bone marrow progenitor populations. Tet2 deficiency promoted renal CCL5 (C-C motif ligand 5) chemokine expression and macrophage infiltration into the kidney. Consistent with macrophage involvement, Tet2 deficiency in myeloid cells promoted hypertension when mice were treated with a subpressor dose of Ang II. The hematopoietic Tet2 −/− condition led to sodium retention, renal inflammasome activation, and elevated levels of IL (interleukin)-1β and IL-18. Analysis of the sodium transporters indicated NCC (sodium-chloride symporter) and NKCC2 (Na + -K + -Cl − cotransporter 2) activation at residues Thr53 and Ser105, respectively. Administration of the NLRP3 (NLR family pyrin domain containing 3) inflammasome inhibitor MCC950 reversed the hypertensive state, sodium retention, and renal transporter activation. CONCLUSIONS: Tet2-mediated CH sensitizes mice to a hypertensive stimulus. Mechanistically, the expansion of hematopoietic Tet2-deficient cells promotes hypertension due to elevated renal immune cell infiltration and activation of the NLRP3 inflammasome, with consequences on sodium retention. These data indicate that carriers of TET2 CH could be at elevated risk for the development of hypertension and that immune modulators could be useful in treating hypertension in this patient population.
Disparities in Emergency Medical Services Use, Prehospital Notification, and Symptom Onset to Arrival in Patients With Acute Stroke
Authors: Regina Royan, Brian Stamm, Timmy Lin, Janette Baird, Christopher J. Becker, Rebecca Karb, Tina M. Burton, Dawn O. Kleindorfer, Shyam Prabhakaran, Tracy E. Madsen
Journal: Circulation (2024)

BACKGROUND: Disparities in time to hospital presentation and prehospital stroke care may be important drivers in inequities in acute stroke treatment rates, functional outcomes, and mortality. It is unknown how patient-level factors, such as race and ethnicity and county-level socioeconomic status, affect these aspects of prehospital stroke care. METHODS: Cross-sectional study of patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage in the Get With the Guidelines-Stroke registry, presenting from July 2015 to December 2019, with symptom onset ≤24 hours. Multivariable logistic regression and quantile regression were used to investigate the outcomes of interest: emergency medical services (EMS) transport (versus private vehicle), EMS prehospital notification (versus no prehospital notification), and stroke symptom onset to time of arrival at the emergency department. Prespecified covariates included patient-level, hospital-level, and county-level characteristics. RESULTS: The inclusion criteria was met by the 606 369 patients. Of the patients, 51.2% were men and 69.9% White, with a median National Institutes of Health Stroke Severity of 4 (IQR, 2–10), and median social deprivation index (SDI) of 51 (IQR, 27–75). Median symptom onset to arrival time was 176 minutes (IQR, 64–565). Black race was significantly associated with prolonged symptom onset to emergency department arrival time (+28.21 minutes [95% CI, 25.59–30.84]), and decreased odds of EMS prehospital notification (OR, 0.80 [95% CI, 0.78–0.82]). SDI was not associated with differences in EMS use but was associated with lower odds of EMS prehospital notification (upper SDI tercile versus lowest, OR, 0.79 [95% CI, 0.78–0.81]). SDI was also significantly associated with stroke symptom onset to emergency department arrival time (upper SDI tercile versus lowest +2.56 minutes [95% CI, 0.58–4.53]). CONCLUSIONS: In this national cross-sectional study, Black race was associated with prolonged symptom onset to time of arrival intervals and significantly decreased odds of EMS prehospital notification, despite similar use of EMS transport. Greater county-level deprivation was also associated with reduced odds of EMS prehospital notification and slightly prolonged stroke symptom onset to emergency department arrival time. Efforts to reduce place-based disparities in stroke care must address significant inequities in prehospital care of acute stroke and continue to address health inequities associated with race and ethnicity.
Fludrocortisone dose–response relationship in septic shock: a randomised phase II trial
Authors: James Walsham, Naomi Hammond, Antje Blumenthal, Jeremy Cohen, John Myburgh, Simon Finfer, David Evans, Sandra Peake, Peter Kruger, James McCullough, Loki Johnk, Dhaval Ghelani, Laurent Billot, Sana Shan, Jason Meyer, Dorrilyn Rajbhandari, Carolyn Koch, Rinaldo Bellomo, Louise M Burrell, Morag Young, Michael Roberts, Lorraine Mackenzie, Gregory Medley, Joshua Dalton, Balasubramanian Venkatesh
Journal: Intensive Care Medicine (2024)
Engineering of Bioresorbable Polymers for Tissue Engineering and Drug Delivery Applications
Authors: Monika Dobrzyńska‐Mizera, Jagan Mohan Dodda, Xiaohua Liu, Monika Knitter, Reece N. Oosterbeek, Pablo Salinas, Eduardo Pozo, Ana Marina Ferreira, Emmanuel Rotimi Sadiku
Journal: Advanced Healthcare Materials (2024)

Abstract Herein, the recent advances in the development of resorbable polymeric‐based biomaterials, their geometrical forms, resorption mechanisms, and their capabilities in various biomedical applications are critically reviewed. A comprehensive discussion of the engineering approaches for the fabrication of polymeric resorbable scaffolds for tissue engineering, drug delivery, surgical, cardiological, aesthetical, dental and cardiovascular applications, are also explained. Furthermore, to understand the internal structures of resorbable scaffolds, representative studies of their evaluation by medical imaging techniques, e.g., cardiac computer tomography, are succinctly highlighted. This approach provides crucial clinical insights which help to improve the materials’ suitable and viable characteristics for them to meet the highly restrictive medical requirements. Finally, the aspects of the legal regulations and the associated challenges in translating research into desirable clinical and marketable materials of polymeric‐based formulations, are presented.
Where are we with gastric cancer screening in Europe in 2024?
Authors: Mārcis Leja
Journal: Gut (2024)

The absolute number of annual cases of gastric cancer in Europe is rising. The Council of the European Union has recommended implementation of gastric cancer screening for countries or regions with a high gastric cancer incidence and death rates. However, as of 2024 no organised gastric cancer screening programme has been launched in Europe. There are several ways to decrease gastric cancer burden, but the screen and treat strategy for Helicobacter pylori (H. pylori ) seems to be the most appropriate for Europe. It has to be noted that increased use of antibiotics would be associated with this strategy. Only organised population-based cancer screening is recommended in the European Union, therefore gastric cancer screening also is expected to fulfil the criteria of an organised screening programme. In this respect, several aspects of screening organisation need to be considered before full implementation of gastric cancer prevention in Europe; the age range of the target group, test types, H. pylori eradication regimens and surveillance strategies are among them. Currently, ongoing projects (GISTAR, EUROHELICAN, TOGAS and EUCanScreen) are expected to provide the missing evidence. Feedback from the decision-makers and the potential target groups, including vulnerable populations, will be important to planning the programme. This paper provides an overview of the recent decisions of the European authorities, the progress towards gastric cancer implementation in Europe and expected challenges. Finally, a potential algorithm for gastric cancer screening in Europe is proposed.
Mannosylated Fluoropolypeptide Nanovaccines Remodeling Tumor Immunosuppressive Microenvironment to Achieve Highly Potent Cancer Immunotherapy
Authors: Meng He, Wei Xu, Yuxin Dan, Yue Pan, Yingying Li, Mingsheng Chen, Chang‐Ming Dong
Journal: Advanced Healthcare Materials (2024)

Abstract It is challenging for nanovaccines (NVs) to effectively deliver antigens/neoantigens to prime specifically potent immunities and remodel immunosuppressive tumor microenvironment (TME) for combating immune “cold” cancers. Herein, a novel kind of mannosylated fluoropolypeptide NVs of MFPCOFG (i.e., mannosylated fluoropoly( D,L ‐cysteine) ovalbumin‐loaded Fe 2+ ‐gallic acid) is designed that synergistically integrates triple antigen‐metal‐thermoimmunity to remodel immunosuppressive TME and achieve highly potent immunities. MFPCOFG plus near‐infrared irradiation (NIR) effectively facilitated antigen uptake and escape, induced the maturation and antigen cross‐presentations of dendritic cells and macrophages, polarized anti‐inflammatory macrophage phenotype M2 into tumoricial M1, primed potent CD4 + /CD8 + T cells responses, proinflammatory cytokines secretion and immune memory effects, showcasing triple antigen‐metal‐thermoimmunity outperforming combo/mono‐immunity. Importantly, both MFPCOFG + NIR and personalized NVs can remarkably enhance the tumor infiltration of CD4 + /CD8 + T and NK cells to boost potent immunities and long‐lasting memory effects, reduce regulatory T (Tregs) and M2 to remodel immunosuppressive TME in B16‐OVA and 4T1 models, achieving superior tumor prevention, ablation, and tumor relapse and metastasis inhibition, as further orchestrated with anti‐PD‐1. Consequently, this work opens up a new avenue to design biocompatible polypeptide nanovaccines with potent immune‐priming and TME‐remodeling capabilities, holding great potentials to combat immune “cold” cancers with clinic‐used anti‐PD‐1 for cancer immunotherapy and personalized immunotherapy.